Logo image
Back
Addition of magnetic resonance imaging to real time trans-rectal ultrasound-based treatment planning for prostate implants
Journal article   Open access   Peer reviewed

Addition of magnetic resonance imaging to real time trans-rectal ultrasound-based treatment planning for prostate implants

Michael Petronek, Salim Balik, Andrei Purysko, Eric Klein, Jay Ciezki and Allan Wilkinson
Journal of contemporary brachytherapy, Vol.11(4), pp.361-369
08/01/2019
DOI: 10.5114/jcb.2019.87189
PMCID: PMC6737565
PMID: 31523238
url
https://doi.org/10.5114/jcb.2019.87189View
Published (Version of record) Open Access

Abstract

Purpose: The greater soft tissue contrast of magnetic resonance imaging (MRI) allows improved accuracy in prostate contouring compared to transrectal ultrasound (TRUS) and helps in identifying specific regions within the prostate. This study attempts to evaluate the potential benefit of MRI-TRUS fusion in treatment planning for more accurate prostate contouring and tumor dose escalation. Material and methods: 14 patients with previous MRI-guided prostate biopsy and an low-dose-rate (LDR) permanent prostate seed implant have been selected. The prostate and tumor (5 patients) were contoured on the MRI images by a radiologist. The prostate was also contoured on TRUS images during LDR procedure together by a urologist and radiation oncologist. MRI and TRUS images were rigidly fused to compare prostate contours in MRI and TRUS. Prostate was then re-contoured by the radiation oncologist using this fusion. Moreover, V-100, V-150, and D-90 differences were evaluated for localized tumor compared to prostate with negative values indicating cold tumor regions. These cases were re-planned to simulate dose escalation. Results: The prostate volume was contoured 8 +/- 10% smaller in TRUS images, compared to MRI images. The mean percent difference in tumor (compared to prostate) V-100 was 0.3 +/--0.4%, V-150 was -0.7 +/--24.8%, and D-90 was 0.2 +/--12.1%. For the posteriorly located tumors (2 cases), V-100 was 0.0 +/--0.3%, D-90 was 9.5 +/--3.0%, and V-150 was 26.1 +/--5.4%. For anteriorly located tumors (3 cases), V-100 was 0.4 +/--0.4%, D-90 was -6.0 +/--11.9%, and V-150 was -18.5 +/--14.4% (became 15.6 +/- 14.6% after re-plan). Conclusions: The MRI-TRUS image fusion is a feasible tool for the visualization of the prostate gland, particularly at the apex and base of the gland. Tumor identification presents the potential for dose escalation using fusion, especially for anteriorly located tumors.
 Life Sciences & Biomedicine Oncology Radiology, Nuclear Medicine & Medical Imaging Science & Technology

Details

Metrics

12 Record Views
1 Times Cited - Web of Science
Logo image